9 Firmen mit Ergebnissen für "therapeutics"

Bio-Technopark Schlieren-Zürich

http://www.bio-technopark.ch/  

8952 Schlieren, Wagistrasse 23

 +41 76 336 99 44
 mario.jenni@bio-technopark.ch

The Bio-Technopark offers professional support for life science start-ups in the setting up and expansion of business activities and promotes interaction between start-ups, academia and industry. A nationally and internationally respected science park has grown up at Schlieren. Through stringent selection, coaching and support, more than 30 successful start-up companies with 750 employees are located here. Eight have been acquired by large corporates, but are still active in the park. Together with 20 institutes and clinics from the University and University Hospital Zurich, an innovative mix of very young and well-established companies and academic research groups has emerged.

Bio-Technopark Schlieren-Zürich

Wagistrasse 23

8952 Schlieren

40 Ergebnisse für "therapeutics" unter Bio-Technopark Schlieren-Zürich

Memo Therapeutics erhält 10,5 Millionen Franken › BIO-TECHNOPARK® S...

... News Memo Therapeutics erhält 10,5 Millionen Franken Schlieren ZH – Die Biotechfirma Memo ... Therapeutics erhält 10,5 Millionen Franken aus dem Förderungsprogramm des Bundes für COVID-19-Arzneimittel ... Memo Therapeutics erhält 10,5 Millionen Franken › BIO-TECHNOPARK® Schlieren-Zürich ... https://www.bio-technopark.ch/news/memo- therapeutics-erhaelt-105-millionen-franken/ ... Memo Therapeutics erhält 10,5 Millionen Franken › BIO-TECHNOPARK® Schlieren-Zürich ...

Memo Therapeutics erhält 37 Millionen Franken › BIO-TECHNOPARK® Sch...

... News Memo Therapeutics erhält 37 Millionen Franken Schlieren ZH – Die Fortschritte von Memo ... Therapeutics bei der Entwicklung neuartiger therapeutischer Antikörper hat bei Investoren Anklang gefunden. In ... Memo Therapeutics erhält 37 Millionen Franken › BIO-TECHNOPARK® Schlieren-Zürich ... https://www.bio-technopark.ch/news/memo- therapeutics-erhaelt-60-millionen-franken/ ... Memo Therapeutics erhält 37 Millionen Franken › BIO-TECHNOPARK® Schlieren-Zürich ...

Mehr Ergebnisse

University of Zurich

https://www.campus-schlieren.uzh.ch/en.html  

8952 Schlieren, Wagistrasse 12

The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.

University of Zurich

Wagistrasse 12

8952 Schlieren

55 Ergebnisse für "therapeutics" unter University of Zurich

UZH - UZH Innovation Hub - UZH Life Sciences Fund investiert in Imm...

... 18.09.2018 UZH Life Sciences Fund investiert in ImmunOs Therapeutics AG UZH Life Sciences Fund ... investiert in ImmunOs Therapeutics AG und unterstützt die weitere Entwicklung der Immuntherapie-Plattform für ... UZH - UZH Innovation Hub - UZH Life Sciences Fund investiert in ImmunOs Therapeutics AG ... UZH - UZH Innovation Hub - UZH Life Sciences Fund investiert in ImmunOs Therapeutics AG Home ... UZH - UZH Innovation Hub - UZH Life Sciences Fund investiert in ImmunOs Therapeutics AG ...

UZH - News - Mit Era-107 den Appetit sanft bändigen

... schwieriger», wie Josua Jordi, Mitgründer des UZH Spin-off EraCal Therapeutics, einräumt. Kampf gegen ... . Hintergrund EraCal Therapeutics ist ein im Jahr 2018 gegründetes Spin-off, das aus der Forschung an der ... LinkedIn Xing Mail Weitere Informationen EraCal Therapeutics Science Advances UZH Innovation Hub UZH ... schwieriger», wie Josua Jordi, Mitgründer des UZH Spin-off EraCal Therapeutics, einräumt. Kampf gegen ...

Mehr Ergebnisse

Somagenetix

https://www.wysszurich.ch/projects/somagenetix  

8952 Schlieren, Wagistrasse 23

Gene therapy solutions for patients with severe inherited diseases.

Somagenetix

Wagistrasse 23

8952 Schlieren

33 Ergebnisse für "therapeutics" unter Somagenetix

UZH - Medizinische Fakultät - Auszeichnung mit mehreren Awards und ...

... , Complex Cardiovascular Catheter Therapeutics, Orlando Florida, USA, 18. Juni 2018 Werner Forssmann Award ... Therapeutics, Orlando Florida, USA, 18. Juni 2018 Werner Forssmann Award, Charité Berlin, Deutschland, 1. Juni ...

UZH - Chair Vokinger - Kerstin Noëlle Vokinger

... , PORTAL (Program on Regulation, Therapeutics, and Law) bei Prof. Aaron Kesselheim, MD, JD, MPH, Harvard ... , Therapeutics, and Law), Harvard Medical School, Boston, USA (www.portalresearch.org) Seit 01. 05. 2019 ... Regulation, Therapeutics, and Law) bei Prof. Aaron Kesselheim, MD, JD, MPH, Harvard Medical School, Boston ...

Mehr Ergebnisse

CUTISS AG

http://cutiss.swiss  

8952 Schlieren, Grabenstrasse 11

 +41 44 244 36 60
 info@cutiss.swiss

After more than 15 years of research (Tissue Biology Research Unit, University Children’s Hospital Zurich), CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.

CUTISS AG

Grabenstrasse 11

8952 Schlieren

7 Ergebnisse für "therapeutics" unter CUTISS AG

... für Healthpoint Therapeutics (Schweiz und USA) sowie die Leitung der Abteilung Manufacturing, Sciences ... Position als Produktionsleiterin am Life Science-Start Up Modex Therapeutics/Isotis in Lausanne, bevor sie ... für Healthpoint Therapeutics (Schweiz und USA) sowie die Leitung der Abteilung Manufacturing, Sciences ... Position als Produktionsleiterin am Life Science-Start Up Modex Therapeutics/Isotis in Lausanne, bevor sie ...

28. Oktober 2019 – CUTISS

... Entwicklungsprojekten für Healthpoint Therapeutics (Schweiz und USA) sowie die Leitung der Abteilung Manufacturing ... der Position als Produktionsleiterin am Life Science-Start Up Modex Therapeutics/Isotis in Lausanne ... Therapeutics (Schweiz und USA) sowie die Leitung der Abteilung Manufacturing, Sciences and Technology (MSAT ... am Life Science-Start Up Modex Therapeutics/Isotis in Lausanne, bevor sie zum DFB Pharmaceuticals ...

Mehr Ergebnisse

Standortförderung Kanton Zürich

https://www.zh.ch/de/volkswirtschaftsdirektion/amt-fuer-wirtschaft/standortfoerderung.html  

8090 Zürich, Walchestrasse 19

 +41 43 259 49 92
 standort@vd.zh.ch

The Division of Business and Economic Development supports resident companies, promotes Zurich's innovation capacity by way of connecting the relevant stakeholders in key industries, fosters external economic relations and offers guidance to companies interested in moving to Zurich.

Standortförderung Kanton Zürich

Walchestrasse 19

8090 Zürich

4 Ergebnisse für "therapeutics" unter Standortförderung Kanton Zürich

Smart Health 2019 | Kanton Zürich

... Perspektiven für «Digital Therapeutics» auf, gefolgt von Tanja Dowe, CEO Debiopharm Innovation Fund, welche die ... Medical Implants». Und für Manolo Bellotto, CEO der Tessiner Gain Therapeutics AG arbeitet daran, bis im ... CTO von Altran Schweiz, Andreas Kuhn, zeigte Trends und Perspektiven für «Digital Therapeutics» auf ... Implants». Und für Manolo Bellotto, CEO der Tessiner Gain Therapeutics AG arbeitet daran, bis im Jahr 2030 ...

Einblicke in die Covid-19-Forschung | Kanton Zürich

... Arzneimittelforschung und Sicherheitsprüfung im Labor zu steigern. Covid-19-Forschung Memo Therapeutics AG MTX ist ein ... Therapeutics, einen hochpotenten SARS-CoV-2-neutralisierenden Antikörper noch im Frühjahr 2021 in der Schweiz ... ™ Lebergeweben zu testen. Memo Therapeutics AG MTX ist ein Spin-off der ETHZ, das eine mikrofluidische ... . Covid-19-Forschung Mit MTX-COVAB plant Memo Therapeutics, einen hochpotenten SARS-CoV-2 ...

Mehr Ergebnisse

University Hospital Zurich​, Research and Education Office

https://www.usz.ch/forschung/Seiten/default.aspx  

8091 Zürich, Rämistrasse 100

The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.

University Hospital Zurich​, Research and Education Office

Rämistrasse 100

8091 Zürich

22 Ergebnisse für "therapeutics" unter University Hospital Zurich​, Research and Education Office

Die Rolle der Epigenetik in Gefässerkrankungen – Universitätsspital...

... mechanisms to therapeutics. Pharmacol Ther. 2019;196:15-43. Xu S, Pelisek J, Jin ZG. Atherosclerosis is an ... mechanisms to therapeutics. Pharmacol Ther. 2019;196:15-43. Xu S, Pelisek J, Jin ZG. Atherosclerosis is an ...

Forschung der Klinik für Angiologie – Universitätsspital Zürich

... ) Bentley InnoMed GmbH (unrestricted grant) Anthos Therapeutics (ASTER & Magnolia trials) Fusszeile ...

Mehr Ergebnisse

Evax AG

http://evax.ch  

8952 Schlieren, Wagistrasse 21


 hello@evax.ch

We are a spin-off company of the University of Zurich, transferring human standards of care into horses. Our research team develops therapeutical vaccines to treat chronic diseases, allergies and respiratory diseases. Our vision is to address diseases in horses with modern research to contribute to the growing knowledge in the pharmaceutical industry.

Evax AG

Wagistrasse 21

8952 Schlieren

1 Ergebnisse für "therapeutics" unter Evax AG

Über uns - EVAX

... .) Administration of newly developed therapeutics during study procedures   Willingness to conduct and manage ... , withdrawal of blood etc.) Administration of newly developed therapeutics during study procedures ...

Kuros Biosciences AG

https://kurosbio.com/  

8952 Schlieren, Wagistrasse 25

 +41 (0)44 733 4747

Our focus is on revolutionizing the field of orthobiologics by developing bone grafts that deliver both targeted and controlled bone healing.

Kuros Biosciences AG

Wagistrasse 25

8952 Schlieren

2 Ergebnisse für "therapeutics" unter Kuros Biosciences AG

... , Zurich, Switzerland CHF 435,459.00 100 % Proteome Therapeutics GmbH, Singen, Germany EUR 25,000.00 100 ... 2007. Prior to co-founding Kuros, Mr. Cowling was co-founder, chairman and CEO of Kuros Therapeutics, a ... , Zurich, Switzerland CHF 435,459.00 100 % Proteome Therapeutics GmbH, Singen, Germany EUR 25,000.00 100 ... 2007. Prior to co-founding Kuros, Mr. Cowling was co-founder, chairman and CEO of Kuros Therapeutics, a ...

... ) effectiveness and safety of the Group’s technology and therapeutics, (v) uncertainty regarding outcome of ... ) effectiveness and safety of the Group’s technology and therapeutics, (v) uncertainty regarding outcome of ...

CSL Vifor

https://www.csl.com/we-are-csl/our-businesses-and-products/csl-vifor  

8952 Schlieren, Zürcherstrasse 39D

 +41 58 851 80 00

Pioneer in iron-based therapies, CSL Vifor is a global leader in iron deficiency and iron deficiency anaemia therapies, with a history dating back to 1872, when pharmacist Caspar Friedrich Hausmann opened a pharmacy in St. Gallen, Switzerland. Since then, we have proven our ability to identify and serve therapeutic areas and patients with significant unmet medical need. Building on our heritage and expertise in iron deficiency therapy, and together with our joint company Vifor Fresenius Medical Care Renal Pharma, today we have a strong and rapidly growing presence in nephrology, and we are committed to launching the next generation of therapies to truly address the full spectrum of kidney disease.

CSL Vifor

Zürcherstrasse 39D

8952 Schlieren

1 Ergebnisse für "therapeutics" unter CSL Vifor

CSL Vifor_Switzerland_DE_14062023_V1_06152023.xlsx

... 6 303,86 CHF N/A N/A 6 2 4 9 N/A N/A 6.82% 2.27% 4.55% N/A Acthera Therapeutics Ltd Basel ... 6 303,86 CHF N/A N/A 6 2 4 9 N/A N/A 6.82% 2.27% 4.55% N/A Acthera Therapeutics Ltd Basel ...

Nach oben